Valneva: Positive Phase 3 Results for COVID-19 Vaccine

Wednesday, 20 October 2021 16:22

covid-19 Vaccine, ValnevaValneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001 that successfully met both co-primary endpoints. Superior neutralizing antibody titer levels compared to active comparator vaccine, AstraZeneca’s AZD1222 (ChAdOx1-S). Neutralizing antibody seroconversion rate above 95%. VLA2001 induced broad T-cell responses with antigen-specific IFN-gamma-producing T-cells against the S, M and N proteins and VLA2001 was well tolerated, demonstrating a statistically significant better tolerability profile compared to active comparator vaccine

Positive Results from the Phase 3 Pivotal Trial

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced positive topline results from the Phase 3 pivotal trial Cov-Compare of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. Valneva’s Chief Executive Officer, Thomas Lingelbach, and the trial’s Chief Investigator, Adam Finn, Professor of Paediatrics at the University of Bristol, will comment on the results in a webcast beginning at 3 p.m. CET today. Please refer to this link:

The pivotal Phase 3, Cov-Compare trial recruited a total of 4,012 participants aged 18 years and older across 26 trial sites in the United Kingdom. The trial met its co-primary endpoints: VLA2001 demonstrated superiority against AZD1222 (ChAdOx1-S), in terms of geometric mean titer for neutralization antibodies (GMT ratio=1.39, p<0.0001), (VLA2001 GMT 803.5 (95% CI: 748.48, 862.59)), (AZD1222(ChAdOx1-S) GMT 576.6 (95% CI 543.6, 611.7)), as well as non-inferiority in terms of seroconversion rates (SCR above 95% in both treatment groups) at two weeks after the second vaccination (i.e. Day 43) in adults aged 30 years and older.

Broad antigen-specific IFN-gamma producing T-cells

T-cell responses analyzed in a sub-set of participants showed that VLA2001 induced broad antigen-specific IFN-gamma producing T-cells reactive against the S- (74.3%), N- (45.9%) and M- (20.3%) protein.

Well tolerated

VLA2001 was generally well tolerated. The tolerability profile of VLA2001 was significantly more favorable compared to the active comparator vaccine. Participants 30 years and older reported significantly fewer solicited adverse events up to seven days after vaccination, both with regards to injection site reactions (73.2% VLA2001 vs. 91.1% AZD1222 (ChAdOx1-S), p<0.0001) and systemic reactions (70.2% VLA2001 vs. 91.1% AZD1222 (ChAdOx1-S), p<0.0001). No unsolicited treatment-related serious adverse events (SAE) have been reported. Less than 1% reported an adverse event of special interest in both treatment groups. Participants in the younger age group vaccinated with VLA2001 showed an overall safety profile comparable to the older age group.

VLA2001 prevented severe COVID-19

The occurrence of COVID-19 cases (exploratory endpoint) was similar between treatment groups. The complete absence of any severe COVID-19 cases may suggest that both vaccines used in the study prevented severe COVID-19 caused by the circulating variant(s) (predominantly Delta).

Adam Finn, Professor of Paediatrics, University of Bristol, Trial Chief Investigator, said: “The low levels of reactogenicity and high functional antibody responses alongside broad T-cell responses seen with this adjuvanted inactivated whole virus vaccine are both impressive and extremely encouraging. This is a much more traditional approach to vaccine manufacture than the vaccines so far deployed in the UK, Europe and North America and these results suggest this vaccine candidate is on track to play an important role in overcoming the pandemic.”

Thomas Lingelbach, Chief Executive Officer of Valneva, said: “These results confirm the advantages often associated with inactivated whole virus vaccines. We are committed to bringing our differentiated vaccine candidate to licensure as quickly as possible and continue to believe that we will be able to make an important contribution to the global fight against the COVID-19 pandemic. We are keen to propose an alternative vaccine solution for people who have not yet been vaccinated.”

Rolling submission for approval

Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, commented: “I would like to thank the trial investigators as well as all trial participants and collaborators, especially the National Institute for Health Research and the clinical teams within the NHS Research Centres as well as Public Health England. This outcome shows the value of the collaboration that we started in September 2020 and we could not have achieved this milestone without them. We’ll continue to work very closely with the MHRA to complete our rolling submission for approval.”

Valneva commenced rolling submission for initial approval with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and is preparing to commence rolling submission for conditional approval with the European Medicines Agency. A final assay validation required by the MHRA to verify the integrity of the VLA2001-301 data remains ongoing and is a prerequisite for final submission of the clinical study report.

As part of the product development strategy, Valneva has completed recruitment of 306 volunteers aged 56 years and older in New Zealand[1] into its VLA2001-304 trial and expects topline data in early 2022. Valneva has also announced the start of recruitment of adolescents as an expansion of the Cov-Compare trial[2].

The Company is preparing for trials in children (5-12 years of age) and a Valneva sponsored booster trial to evaluate VLA2001’s booster performance for people in need of a booster.

About Phase 3 Trial Cov-Compare (VLA2001-301)

Cov-Compare (VLA2001-301) is a randomized, observer-blind, controlled, comparative immunogenicity trial in 4,012 adults and 660 adolescents. Co-Primary immunogenicity endpoints are superiority of GMT ratio of VLA2001 compared to AZD1222 (ChAdOx1-S) as well as non-inferiority of seroconversion rates of neutralizing antibodies administered in a two-dose immunization schedule four weeks apart, measured at two weeks after the second vaccination (i.e. Day 43) in adults aged 30 years and older. It also evaluates the safety and tolerability of VLA2001 at two weeks after the second vaccination in adults and adolescents aged 12 years and older. The trial is being conducted at 26 sites across the U.K. 2,972 participants 30 years of age and older were randomized in a 2:1 ratio to receive two intramuscular doses of either VLA2001 (n=1,977) or AZD1222 (ChAdOx1-S) (n=995) at the recommended dose level, 28 days apart, on Days 1 and 29. For immunogenicity analyses, samples from 990 participants (492 vaccinated with VLA2001, 498 vaccinated with AZD1222 (ChAdOx1-S)) who tested sero-negative for SARS-CoV-2 at screening were analyzed. 1,040 participants that are under 30 years of age were recruited in a non-randomized treatment group and received VLA2001 28 days apart. Safety data on those participants 18-29 years of age are analyzed in parallel to the adults 30 years of age and above. Recently, the trial commenced enrolling the first adolescent participants.

About VLA2001

VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate against COVID-19 in clinical trials in Europe. It is intended for active immunization of at-risk populations to prevent carriage and symptomatic infection with COVID-19 during the ongoing pandemic and potentially later for routine vaccination including addressing new variants. VLA2001 may also be suited for boosting, as repeat booster vaccinations have been shown to work well with whole virus inactivated vaccines. VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology for Valneva’s licensed Japanese encephalitis vaccine, IXIARO®. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018. This adjuvant combination has consistently induced higher antibody levels in preclinical experiments than alum-only formulations and shown a shift of the immune response towards Th1. CpG 1018 adjuvant, supplied by Dynavax Technologies Corporation (Nasdaq: DVAX), is a component of the US FDA- and EMA-approved HEPLISAV-B® vaccine. The manufacturing process for VLA2001, which has already been upscaled to final industrial scale, includes chemical inactivation to preserve the native structure of the S-protein. VLA2001 is expected to conform with standard cold chain requirements (2 degrees to 8 degrees Celsius).

About Valneva SE

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.


Quelle: Valneva
Foto: (c) CDC

Bei Rückfragen zum Artikel wenden Sie sich
bitte direkt an die im Artikel angegebene Kontaktadresse.

.fusion-widget-area-1 {padding:0px 0px 0px 0px;}.fusion-widget-area-1 .widget h4 {color:#4c5166;}.fusion-widget-area-1 .widget .heading h4 {color:#4c5166;}.fusion-widget-area-1 .widget h4 {font-size:24px;}.fusion-widget-area-1 .widget .heading h4 {font-size:24px;}
jobbörse für Naturwissenschaftler

Der Beitrag Valneva: Positive Phase 3 Results for COVID-19 Vaccine erschien zuerst auf Jobbörse und Netzwerk für Naturwissenschaftler /-innen.

Read more

Published in life-science
  • FEMS - Get Involved bulletin – November 2021
    The FEMS Get involved bulletin is out! Read the October issue with microbiology research, events and calls. In this bulletin: FEMS Industry Placement Grants Congress Attendance Grant Meeting Organizer Grant, Research and Training Grant New podcast episode FEMS Journal News Opportunities and other news   The ÖGMBT has a very wide international network and is a member of several relevant scientific societies like FEMS. ÖGMBT members are automatically members of…
  • FEMS Affiliates Letter - November 2021
    As member of the ÖGMBT you are automatically also member of the Federation of European Microbiology Societies (FEMS). The FEMS Affiliates Letter of November 2021 has the following content:   1. Microbiology News and Events 2. The FEMS Journals 3. Policy Corner 4. Grants Corner 5. Opportunities 6. Extras    
  • LS2 Annual Meeting 2022
    LS2 Annual Meeting 2022 on the topic “Life Sciences in the 2020s: quantitation, integration and prediction", will be held on February 17 and 18, 2022, together with the Young Scientists' Satellite on February 16, 2022 in Zurich, at campus Irchel of the University of Zurich. The program will include 3 plenary lectures, Nevan Krogan (University of California San Francisco), Anne-Claude Gingras (Lunenfeld-Tanenbaum Research Institute. Toronto) and Marnix H. Medema (Wageningen…
  • FEMS Grant for industry placement
    As Early Career Scientist, you can apply similar to a Research & Training Grant, but with an industry of your choice as your host. Also non-laboratory work can be considered, as long as relevant for microbiology (ie communications, patenting, quality control, advocacy, etc). What are you waiting for? Get in touch with the industry of your choice and start creating a working plan. Next deadline is February 1st 2022. More…
  • FEMS Affiliates Letter - October 2021
    As member of the ÖGMBT you are automatically also member of the Federation of European Microbiology Societies (FEMS). The FEMS Affiliates Letter of October 2021 has the following content:   1. Microbiology News and Events 2. The FEMS Journals 3. Grants Corner 4. Opportunities 5. Extras
  • FEMS - Get Involved bulletin – October 2021
    The FEMS Get involved bulletin is out! Read the October issue with microbiology research, events and calls. In this bulletin: FEMS Industry Placement Grants FEMS Conference in Belgrade 2022 FEMS Journal News Grants corner, opportunities and other news   The ÖGMBT has a very wide international network and is a member of several relevant scientific societies like FEMS. ÖGMBT members are automatically members of these societies and are entitled to…
  • ÖGMBT members can now choose to publish open access articles in two FEBS journals
    FEBS is pleased to announce that ÖGMBT members can now choose to publish open access articles in two FEBS  journals (The FEBS Journal and FEBS Letters) at no direct cost. In February 2021, Wiley, FEBS’ publishing partner, agreed a 3-year combined open access publication and subscription agreement with the Austrian Academic Library Consortium (KEMÖ) and the Austrian Science Fund (FWF). Researchers at affiliated institutes will be able to both access…
  • EMBO Women in Science Award - Deadline 15th October
    Nominations are invited for the 2022 FEBS | EMBO Women in Science Award.  The deadline is next Friday, 15th October. Full details can be seen here:
  • ÖGMBT congratulates Markus Schosserer!
    Welche Veränderungen durchlebt unser Organismus, während wir altern? Die Biotechnologen Johannes Grillari und Markus Schosserer haben es sich zur Aufgabe gemacht, dem gesunden Altwerden auf Zellebene auf die Spur zu gehen. Inzwischen ist es ihnen gelungen, das Leben von Fliegen, Würmern und Hefezellen zu verlängern und gleichzeitig deren Fitness zu steigern. Dies gelang durch Veränderungen an den Ribosomen.   Originalartikel
  • FEMS Affiliates Letter - September 2021
    As member of the ÖGMBT you are automatically also member of the Federation of European Microbiology Societies (FEMS). The FEMS Affiliates Letter of September 2021 has the following content:   1. Microbiology News and Events 2. The FEMS Journals 3. Policy Corner 4. Grants Corner 5. Opportunities 6. Extras  
  • Present-Day Practicals symposium from LabBuddy
    On the 27th of January 2022, we welcome you to the 4th edition of the Present-Day Practicals symposium. During this interactive (online) event you will get the chance to get inspired by (international) colleagues, and to learn from both their challenges and their successes. Together, we will discuss the lessons learned and highlight opportunities for future laboratory teaching. The Present-day Practicals symposium aims at increasing the quality of laboratory education based on recent…
  • Winter School Revise & Revitalize- LBG Career Center
    From 8 – 12 February 2021, the LBG Career Center is offering an inaugural 5-day Winter School for pre- and post-docs of the Ludwig Boltzmann Gesellschaft as well as other research organizations and universities. The goal of the Winter School Revise & Revitalize is to demystify the unwritten rules of writing and presenting to enable researchers to communicate their research successfully.
  • YSF (Young Scientists Forum) 2022 Portugal
    2022 IUBMB–FEBS–PABMB Young Scientists’ Forum (YSF 2022) will be held just ahead of – and in conjunction with – the joint 25th IUBMB, 46th FEBS and 15th PABMB Congress. The exciting YSF 2022 will take place at Vimeiro, located on the Portuguese coast alongside a peaceful beach with a fantastic view of the endless Atlantic Ocean. The YSF 2022 meeting will bring together around 120 selected young researchers in biochemistry…
  • Neues Leadership-Programm für Innovatorinnen
    Jetzt bewerben für INNOVATORINNEN LEADERSHIP Anfang 2022 startet der neue, von der FFG (Österreichische Forschungsförderungsgesellschaft) begleitete Durchgang für Gestalterinnen (powered by BMDW). Für alle, die ihre F&I-Missionen entfalten, neue Netzwerk-Kontakte aufbauen und zu mehr beruflichen Gestaltungsspielräumen gelangen möchten. Am 2.Dezember gibt die FFG Einblick in die Bewerbungsmöglichkeit bei einem Info-Webinar. INNOVATORINNEN ist Empowerment und Peer-Group-Austausch kombiniert mit Innovationssession (z.B.  Co-Creation, Visual-, System- & Design-Thinking, LEGO© Serious Play©), um Innovatorinnen und…
  • IUBMB grants
    IUBMB grants- There is variety of travel and fellowship grants for young researchers from International Union of Biochemistry and Molecular Biology with upcoming deadlines.  Check it out here.
  • FEBS-IUBMB-ENABLE 2022 Symposium – a PhD and Postdoc meeting
    FEBS-IUBMB-ENABLE are now looking for an academic institution (either a university or a research institution) in Europe with a strong research background in molecular life sciences and an active PhD community to host the November 2022 conference. This event will be organized by a committee of young researchers belonging to the four ENABLE institutions (core institutions, as listed above) plus the selected host institution (associated institution). It will be organized…
  • FEBS junior initiative
    To bring together young scientists from all over Europe, the junior sections of the ÖGMBT (Austria), SIB (Italy), SEBBM (Spain) and GBM (Germany) have collaborated with FEBS to establish a platform for exchange within the FEBS Network. For this, FEBS has created an open Room for the Junior Sections of FEBS Constituent Societies. All young members from the FEBS societies are welcome to sign up to the FEBS Network and become a member of the room using the following…
  • Explaining THT Biomaterials in 3 Minutes to Scientists
    This is our supplemental 3 minute video for the 11th World Congress on Alternatives and Animal Use in the Life Sciences (WC11) from 23 August - 2 September 2021, our abstract ID=625: Enjoy watching (and sorry for the poor sound - we will improve)!
  • Summer School LEAD_able from LBG career center
    LINK: Das LBG Career Center bietet im Sommer 2020 zum zweiten Mal eine Summer School für Pre- und Post-Docs (NachwuchswissenschafterInnen) der Ludwig Boltzmann Gesellschaft, sowie anderer Forschungsorganisationen und Universitäten an. Das Ziel der intensiven 6-tägigen Summer School LEAD_able ist, sich kompakt Transferable Skills für eine (Führungs-)Karriere in oder außerhalb der Wissenschaft anzueignen und professionell begleitet über die individuelle Karriereentwicklung zu reflektieren.  Skills Trainings zu 4 Themenschwerpunkten, ein spezielles GENtoring (alters-, geschlechts-…
  • Journal “Cell Communications and Signaling” invites you to submit abstracts
    Journal "Cell Communications and Signaling" invites you to submit to our new thematic series: Extracellular Vesicles in Infectious Disease   This new thematic series focuses on the role of EVs in bacterial and viral infections. This includes EVs released from infected host cells that contain antimicrobial compounds, outer membrane vesicles (OMVs) derived from bacterial pathogens or viruses, which strongly resemble mammalian EVs. Increasing knowledge of pathogen- and host cell-derived EVs…
  • Wie die Gedanken so das Verhalten
    Eine Zeitung zu lesen, egal ob im Internet oder ausgedruckt, ist wie einem Menschen zuzuhören. Stell dir vor, du hörst permanent einem notorischen Nörgler zu, der immer und überall ein Haar in der Suppe findet, der sich an nichts freuen kann, der nur Probleme sieht, der nur von den schlechten Seiten der Menschen erzählt. Welches Weltbild würdest du...
  • Trockenheit durch Verlust der Schneedecke
    Der fehlende Schnee verschärft neben der Verstädterung und dem steigenden Wasserbedarf in Landwirtschaft und Industrie zusätzlich die Ausmaße der Trockenheit. Der Iran leidet nach Angaben der Vereinten Nationen seit fast 30 Jahren unter Dürre, wobei sich die Situation zunehmend verschärft. Eine neue Studie der Universität Graz in Zusammenarbeit mit...
  • Invasive Säugetiere als Gefahr für Gesundheit
    Invasive Säugetiere können in Europa auch zur Gefahr für Gesundheit und Biodiversität werden. Die Verbreitung eingeschleppter Arten und potenzieller Krankheitserreger wird durch den Klimawandel begünstigt.Invasive Säuger verdrängen heimische ArtenWaschbär, Marderhund, Grauhörnchen, Nutria – putzige Säugetiere, die eines gemeinsam haben: Sie kamen u...
  • Inactivated Covid-19 vaccine of Valneva is expected for 2nd Q 2022
    Valneva SE has signed an Advance Purchase Agreement (APA) with the European Commission (EC) to supply up to 60 million doses of its inactivated COVID-19 vaccine candidate, VLA2001, over two years. Valneva expects to deliver 24.3 million doses during the second and third quarters of 2022, subject to approval of VLA2001 by the European Medicines...
  • Uni Innsbruck beweist hohes Potenzial für Firmengründungen
    Mit 11 Spin-offs in der Zeit von 2018 – Juni 2021 liegt die Uni Innsbruck vor allen anderen österreichischen Universitäten. In der Gesamtwertung der „Leading Austrian Institutions“, die im Rahmen der Spin-Off-Austria-Konferenz 2021 ausgezeichnet wurden, belegte die Universität Innsbruck den 3. Platz. Insgesamt waren 51 Universitäten und...
  • Aufbruch in eine neue Welt
    Aufbruch in eine Neue Welt NOISIV im Tempel der Macht widmet sich in jedem Kapitel einem ganz spezifischen Thema, das uns im täglichen Leben nur allzuoft begegnet. Es sind Verhaltensweisen skizzenhaft beschrieben, die nur allzu menschlich sind. Wenn Du mit etwas Distanz darauf blickst, wird es Dir vielleicht selbst seltsam vorkommen, wie wir uns...
  • Menschliches Wohlergehen anstelle von Wirtschaftswachstum
    Im Wettlauf an die ökologischen Grenzen unseres Planeten stellte ein britisch- österreichisches Forschungsteam 148 Länder auf dem Prüfstand. Kein Land der Erde erreichte in den vergangenen drei Jahrzehnten soziale Mindestanforderungen, ohne dabei ökologische Grenzen zu übertreten. Das fand ein britisches Forschungsteam unter Beteiligung der BOKU...
  • Keine Panik vor der Angst
    “Vielleicht haben sie Angst davor, sich die Angst selbst einzugestehen? Sie haben Angst, als schwach abgestempelt zu werden. Dabei erfordert es ganz schön viel Mut und Stärke, der Angst vorbehaltlos in die Augen zu sehen.”Seite 37Nur keine Panik vor der Angst. Angst ist ein archaisches Gefühl, das den Menschen seit Jahrtausenden vor...
  • Anapur AG
    anapur AGVirtueller Dialog –Computersystem meets GxP // Entwicklungen, Chancen, Risiken23. Nov. 202115:30 – 17.30 UhrUnternehmen müssen sich laufend an Entwicklungen in ihrem Umfeld anpassen, auch in regulierten Bereichen. Diese Entwicklungen können positiv sein, wie neue Technologien die effizientere Prozesse ermöglichen. Sie können aber auc...
  • Willkommen bei life-science
    Jobbörse und Netzwerk für Naturwissenschaftler /-innen.fusion-body .fusion-builder-column-0{width:100% !important;margin-top : 0px;margin-bottom : 0px;}.fusion-builder-column-0 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px...